Vaxart outlines Phase IIb COVID-19 top line data in first half of 2027 backed by BARDA funding (OTCMKTS:VXRT)
· seekingalpha.com
Vaxart (VXRT) Q2 2026 earnings call recap: Phase IIb oral COVID pill vaccine safety update, BARDA funding, cash runway, and 2027 catalysts—read now.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...